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Abstract: 
The direct association of the genome, transcriptome, metabolome, lipidome and 
proteome with the serum glycome has revealed systems of interconnected cellular 
pathways. The exact roles of individual glycoproteomes in the context of disease have 
yet to be elucidated. In a move towards personalized medicine, it is now becoming 
critical to understand disease pathogenesis, and the traits, stages, phenotypes and 
molecular features that accompany it, as the disruption of a whole system. To this end, 
we have developed an innovative technology on an automated platform, 
“GlycoSeqCap”, which combines N-glycosylation data from six glycoproteins using a 
single source of human serum.  Specifically, we multiplexed and optimised a 
successive serial capture and glycoanalysis of six purified glycoproteins, 
immunoglobulin G (IgG), immunoglobulin M (IgM), immunoglobulin A (IgA), transferrin 
(Trf), haptoglobin (Hpt) and alpha-1-antitrypsin (A1AT), from 50µl of human serum. 
We provide the most comprehensive and in-depth glycan analysis of individual 
glycoproteins in a single source of human serum to date. To demonstrate the 
technological application in the context of a disease model, we performed a pilot study 
in an ovarian cancer cohort (n=34) using discrimination and classification analyses to 
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identify aberrant glycosylation. In our sample cohort, we exhibit improved selectivity 
and specificity over the currently used biomarker for ovarian cancer, CA-125, for early 
stage ovarian cancer. This technology will establish a new state-of-the-art strategy for 
the characterization of individual serum glycoproteomes as a diagnostic and 
monitoring tool which represents a major step towards understanding the changes that 
take place during disease. 
 
Introduction: 
Glycosylation is the most common and complex type of post-translational modification 
and glycoscience is rightly recognised as a current frontier. Over 1% of total human 
genome codes for approximately 300 functional glycogenes known to exist in 
humans1. Post-translational modifications (PTMs) of a protein are critical late events 
in protein biosynthesis and glycosylation is one of the most important. It reflects the 
genome of the individual person and also the many other influences on the cellular 
pathways. In fact, the glycoproteome can be thought of as the final readout of the 
genome that confers function on the gene products. A range of human genetic 
disorders, including congenital disorders of glycosylation2,3, MODY type diabetes4, 
galactosemia5 and muscular dystrophies6 have been directly linked to or shown to 
involve faulty glycosylation. Cancer associated aberrant gene regulation also results 
in alterations of glycan structures and has been well studied both in the serum glycome 
and specific serum glycoproteins7-9. In addition, chronic inflammatory diseases display 
altered glycosylation10. 
Immunoglobulin G (IgG) N-glycome is well characterised using liquid chromatography 
and mass spectrometry methods,11-13 but N-glycosylation analysis of other 
glycoproteins has been studied to a far lesser extent. For example, N-glycosylation 
analysis of acute phase proteins, such as transferrin (Trf), alpha-1-antitrypsin (A1AT) 
and haptoglobin (Hpt), has been conducted in our laboratory8,14 using complex 
methodologies such as isoelectric focussing (IEF) or 2D-gel electrophoresis for 
glycoprotein separation. In addition, N-glycosylation of serum immunoglobulin M 
(IgM)15 and immunoglobulin A (IgA)16 have been characterized previously using 
normal phase high performance liquid chromatography (NP-HPLC) a decade ago with 
only a proportion of the glycans identified, a limitation of the technology at the time. 
More recently, IgA site specific glycosylation (N- and O-glycopeptides from IgA1) was 
elucidated in serum of patients with rheumatoid arthritis (RA) during pregnancy using 
matrix-assisted laser/desorption ionisation Fourier transform ion cyclotron resonance 













(MALDI-FTICR) mass spectrometry17. Of note, the team additionally performed 
released N-glycan analysis and could identify major N-glycans that were not identified 
in the characterized IgA1 N-glycopeptide fractions. As such, a detailed structural 
characterization of serum IgA N-glycome analysis remains to be undertaken. In a 
separate study, protein-specific differential glycosylation of immunoglobulins (IgG, IgM 
and IgA) were studied in serum of ovarian cancer patients18 using multiple reaction 
monitoring on a triple quadrupole mass spectrometer. This technology presents similar 
limitations as to the total structural elucidation of the N-glycome, but is highly revealing, 
whereby the authors hypothesize that within the total serum glycome profile, which is 
largely dominated by the highest abundance proteins (such as antibodies IgG, IgM 
and IgA or acute phase proteins Trf, Hpt, A1AT) that protein- and site-specific 
glycosylation profiles will be likely to provide further insights into protein specific 
alterations in glycosylation of the glycans related to ovarian cancer as well as serve 
as more specific biomarkers for ovarian cancer than current tools18. 
Although some advances have been made in the sample purification and target 
glycoprotein enrichment19, there is a growing necessity for the development of more 
robust, consistent, sensitive and versatile methods that can be automated and applied 
to personalized medicine approaches. To address this need, we optimised and 
automated a glycoanalytical technology to capture and glycoprofile six abundant 
individual glycoproteins by serial extraction-IgG, IgM, IgA, Trf, Hpt and A1AT. We 
performed a detailed analysis of the N-glycomes from these six glycoproteins using 
50 µl of pooled normal human serum (NHS). Then we applied this technology to an 
ovarian cancer patient cohort, consisting of 7 healthy controls, 6 borderline and 21 
metastatic ovarian cancer patients and tested its potential to be used as a diagnostic 
tool for earlier detection of ovarian cancer. This study is a follow-up of our previously 
reported sample preparation and chromatography technologies for glycan 
analysis11,20,21 and biomarker discovery.  
Experimental: 
Serum samples 
Normal Human Serum (NHS) samples were used as described previously20. Briefly 
human adult serum sample from healthy male and female blood donors were pooled 
and used as a source of glycoproteins for subsequent glycan analysis (courtesy of the 
U.K. Blood Transfusion Service). Serum samples from 7 healthy women (hereafter 













called normal) and 27 ovarian cancer patients classified as either metastatic (n=21) or 
borderline (n=6) were used for the GlycoSeqCap technology (Supporting Tables S9) 
following ethical approval and obtaining informed consent. After allowing the blood to 
clot for 30-60min, serum was obtained by centrifugation at 2,000g for 10min and stored 
at -80oC until analysis.  
Chemicals and Reagents 
All chemical reagents and solvents were purchased from Sigma-Aldrich. Pre-packed 
Protein G (PTH93-20-02)  300µL tip columns obtained from PhyNexus Inc. Albumin 
(Cat 191297005),  IgM (Cat# 289005), IgA(Cat# 190288005), Trf (Cat# 191306005) 
and A1AT (Cat# 191287005) affinity matrix resins were obtained from Life 
Technologies CaptureSelect TM and Hpt (Cat# 291.2950.05) obtained from BAC BV, 
Capture Select. Exoglycosidase and PNGase F enzymes were obtained from NEB: 
PNGase F (P0709L), Bovine Kidney Fucosidase (BKF, P0748S), and other 
exoglycosidases Arthrobacteria sialidase (ABS, PZGK80090), Bovine Testes 
Galactosidase (BTG, PZGKX-5013), N-Acetyl Hexosaminidase (GUH, PZGK80050), 
and Jack Bean Mannosidase (JBM, GKX-5003) obtained from Europa (Prozyme). 
Solid-supported Ultralink hydrazide (Cat# 11809410) and Fermentas PageRuler Pre-
stained Protein Ladder (Cat# 11832124) was obtained from Fisher Scientific. The 
following plates were used;1μm 96 well (PALL Acroprep Advance 350, VWR 518-
0026), 96 well 2mL collection plate (X50 MICROPLATE, Fisher, 11511963), 96 well 
assay (Greiner, 450μl, Cruinn 731-1372), 384 well ultrafiltration (Acroprep, 10KDa, 
PALL 5077), 384 well PCR (Fisher, Armadillo AB-2384/O, orange, 30μl, VWR 732 
1578) and a 384 well storage/collection (Corning, 240μl VWR 736 0202 3347). 
Reagents were placed on the robotic platform in a 12 well reagent trough (VWR 732-
1390). Samples were prepared on a Hamilton robotics StarLet liquid-handling 
platform. The instrument is equipped with eight software-controlled pipettes, a vacuum 
manifold, and an automated heater shaker. Samples were analysed on a Waters 
Acquity H-class UPLC instrument. The following workflow was implemented as robotic 
program on Hamilton Robotics Venus One software. 
 
Custom Phytip Glycoprotein affinity matrix resin tip columns preparation 
Each specific anti-protein and anti-glycoprotein matrix was packed in Phytips by 
PhyNexus Inc. Briefly, 20µL each of Albumin, IgG, IgM, IgA, Trf, and A1AT affinity 













matrix resins purchased from Life Technologies CaptureSelect TM and Hpt purchased 
from BAC BV were packed individually in a 300μL Hamilton tips. 
 
Phytip Glycoprotein Affinity Purification 
Glycoproteins from 50μL of whole serum sample were captured in the following 
sequence: Albumin, Trf, IgG, IgM, IgA, Hpt and A1AT on the automated liquid handling 
station (Hamilton Starlet) in a 96-well format using the custom Phytips (Figure 1). In 
this method Phytip equilibration, capture, wash and elution refers to cycling a solution 
through the resin bed for a fixed number of aspirations and dispense steps termed 
cycles at defined flow rates. In a sequential fashion Albumin and the glycoproteins 
were captured from serum or from serum depleted of the preceding glycoproteins. For 
example, in the case of Trf, the Albumin depleted serum was used for the affinity 
chromatography. In the case of IgG affinity, the serum was depleted of both Albumin 
and Trf prior to IgG purification.  
Albumin and the glycoproteins were captured using Phytips from serum/depleted 
serum in 96-well Greiner plates (50µL per well, 100µL mixing volume, 6 cycles, 
20μL/s) using pre-equilibrated Phytips (200μL per well, 0.1M sodium phosphate buffer, 
0.15M NaCl, pH 7.4, 3 cycles, 5μL/s). The Albumin/glycoprotein in Phytip resin were 
washed three times in 96 well Collection plates, each containing binding buffer (170µL 
per well mixing volume, 0.1M sodium phosphate buffer, 0.15M NaCl, pH 7.4, 6 cycles, 
5μL/s) followed by treatment with washing buffer (170 µL per well mixing volume, 1% 
NaCl + 1g/L NaN3,, 4 cycles, 5μL/s). The Albumin/glycoproteins were eluted (80μL per 
well, 0.2M Glycine-HCl buffer, pH 2.5, 3 cycles, 4μL/s) into three Greiner plates. 
Neutralisation buffer (10μL per well, 1M Tris-HCl buffer, pH 9.0) was added to two 
Greiner plates and the samples were pooled together for two Greiner plates (180μL 
resulting solution per well, mean concentrations 0.22, 0.90,  0.85, 0.12, 0.81 and 
0.79mg/mL respectively for IgG, IgM, IgA, Trf, Hpt and A1AT). 
1D SDS-PAGE 
Affinity purified glycoproteins were reduced and loaded on SDS-PAGE gels 
(NuPAGE® Novex 4–12% Bis–Tris) and separated in a XCell SureLock™ Mini-Cell 
(Invitrogen, Carlsbad, CA) for 90min at 120V using a MES running buffer. 5μg of total 
protein was loaded in each lane of the gel. Once electrophoretic separation was 













completed, proteins were visualized by staining with Coomassie blue staining solution 
followed by destaining with multiple changes of deionised water (Figure 1). 
Automated glycoprotein denaturation and N-Glycan release 
As described previously22, briefly N-glycan analysis was performed using a pooled 
serum sample from 100 apparently healthy male and female adult blood donors (U.K. 
Blood Transfusion Service). The antibodies IgG, IgA, IgM and the acute phase 
proteins Trf, Hpt and A1AT were purified from the pool using the respective affinity 
resin (Life Technologies) packed in Phynexus Phytips as previously described (in 
above section). On an automated platform, the glycoprotein samples were dispensed 
into two 384-well ultrafiltration plates (maximum loading: 60μg protein, 10kDa). Ultra-
filtration was performed by centrifugation (3700g, 30min, room temperature) or on a 
vacuum manifold (> 25 in Hg vacuum, 30min). Denaturation buffer (25μL per well, 
100mM sodium bicarbonate, 50mM dithiothreitol (DTT), 0.1% sodium dodecyl sulfate 
(SDS)) was dispensed into 2 × 384 well ultrafiltration plates. After 10min incubation at 
room temperature, the samples were mixed 10 times (mixing volume: 15μL, flow rate: 
10μL/s) and transferred to a 384-well PCR plate (Armadillo). The plate was placed into 
a robotic incubation chamber at 95°C for 10min. The plate was removed from the 
incubator and equilibrated to room temperature for 10min. 1M iodoacetamide (IAA), 
10μL, was dispensed into each well of the ultrafiltration plate and the samples (25μl) 
were transferred back into the 384 well PCR plate. The samples were mixed 5 times 
(mixing volume 20μL, flow rate, 10μL/s). After 10min incubation at room temperature, 
the ultrafiltration plate was stacked onto a 240μL collection plate (Corning block) and 
centrifuged (3700g, 30min, room temperature) and the supernatant was removed. 
Next, 10μL of a 25mM sodium bi-carbonate solution was dispensed into each well and 
the ultra-filtration plate was centrifuged (3700g, 30min, room temperature) and the 
supernatant was removed. 
The deglycosylation mix, 12μL (0.4μl of PNGase F (2.5U/mL), 25mM sodium 
bicarbonate) was dispensed into each well and the plate was then covered with a lid 
and incubated on a robotic orbital shaker (shaking orbit: 2mm, shaking speed: 700rpm, 
temperature: 38°C, incubation time: 30min). The ultrafiltration plate was stacked onto 
a 30 μL/well PCR plate (Armadillo) and centrifuged (3700g, 10min, room temperature). 
Finally, 10μL of 25M sodium bicarbonate solution was dispensed into each well of the 
ultrafiltration plate (still stacked onto the PCR plate) and the assembly was centrifuged 













(3700g, 10min, room temperature). The released N-glycans in the PCR plate were 
subsequently fluorescently labelled. For glycan labelling, 5μL of glycan sample (PCR 
plate) was transferred to a 95μL Corning block and 11.6μL of AQC (3mg/mL MeCN) 
was added. 3μL of this crude mixture was directly injected into the UPLC system. 
Alternatively, after the PNGase F release, glycans can be frozen and are stable at -
20°C for labelling later. 
Ultra-Performance Liquid Chromatography (UPLC) 
As previously described22, briefly the separation of AQC-derivatized N-glycans was 
carried out by UPLC with fluorescence detection on a Waters ACQUITY UPLC H-
Class instrument consisting of a binary solvent manager, sample manager, and 
fluorescence detector under the control of Empower 3 software (Waters, Milford, MA, 
USA). The HILIC separations were performed using a Waters Ethylene Bridged Hybrid 
(BEH) Glycan column (150 × 2.1mm i.d., 1.7 μm particles) with 50mM ammonium 
formate (pH 4.4) as solvent A and MeCN as solvent B. The column was fitted with an 
ACQUITY in-line 0.2μm filter. The separation was performed using a linear gradient of 
70−53% MCN 0.56mL/min in 16.5min for IgG N-glycan separation. An injection 
volume of 3μL prepared in 70% v/v MeCN was used throughout. Samples were 
maintained at 5°C prior to injection, and the separation temperature was 40°C. The 
FLD excitation /emission wavelength were λex = 245nm and λem = 395nm, 
respectively. The system was calibrated using an external standard of hydrolyzed and 
2-AB-labeled glucose oligomers to create a dextran ladder, as described previously11. 
A fifth-order polynomial distribution curve was fitted to the dextran ladder to assign 
glucose unit (GU) values from retention times (using Empower software from Waters).  
 
Liquid Chromatography-Mass Spectrometry (LC-MS)  
Online coupled fluorescence (FLR)-mass spectrometry detection was performed using 
a Waters Xevo G2 QTof with Acquity® UPLC (Waters Corporation, Milford, MA, USA) 
and BEH Glycan column (2.1 x 150mm, 1.7μm particle size). For MS acquisition data 
the instrument was operated in positive-sensitivity mode with a capillary voltage of 
3kV. The ion source block and nitrogen desolvation gas temperatures were set at 
120°C and 350°C, respectively. The desolvation gas was set to a flow rate of 800L/h. 
The cone voltage was maintained at 40V. Full-scan data for glycans were acquired 
over m/z range of 300 to 2000. Data collection and processing were controlled by 













MassLynx 4.1 software (Waters Corporation, Milford, MA, USA). The fluorescence 
detector settings were as follows: λexcitation: 245nm, λemission: 395nm; data rate 
was 10pts/second and a PMT gain = 20. Sample injection volume was 10μL (75% 
MeCN). The flow rate was 0.400mL/min (unless specified) and column temperature 
was maintained at 60°C; solvent A was 50mM ammonium formate (pH 4.4) and 
solvent B was MeCN. A 60min linear gradient was used and was as follows: 25-46% 
A for 35min, 46-80% A for 8min (flow rate at 0.2mL/min), 80-25% A for 27min. To avoid 
contamination of system, flow was sent to waste for the first 1.2min and after 55min. 
 
Exoglycosidase digestions 
The AQC labelled N-glycans from the glycoproteins (IgG, IgM, IgA, Trf, Hpt and A1AT) 
purified from healthy human serum were treated with exoglycosidases according to 
the literature procedure23. For enzymes ABS (Arthrobacter ureafaciens sialidase), 
BTG (Bovine testes beta-galactosidase), GUH (β-N-(1-2,3,4,6) 
Acetylglucosaminidase S), BKF (Bovine kidney alpha-fucosidase) and JBM (α1-2,3,6 
Mannosidase J, Jack Bean): 1, 2, 2, 4 and 4μl of each was used per digestion to give 
the final concentrations of 0.5, 1, 8, 3200 and 60U/mL respectively. All digestions were 
carried out in a final volume of 10μl, at 50mM NaOAc pH 5.5 for 24h-96h.  
 
Computational procedures 
Statistical analysis: Variables age, menopause status, logCA125, C-reactive protein 
levels (CRP), protein titre and glycan peak areas between patients and controls were 
compared using a Tukey honest significant difference (HSD) test with ANOVA. Peak 
areas are compositional data (presented as a % of the total area under the graph) and 
therefore the constant-sum constraint (CSC) occurs. The CSC means individual 
variables do not vary independently, violating common assumptions upon which 
standard statistical analyses are performed. This was avoided by performing a log 
transform, log(Peaki)/(100-Peaki), on all peak areas24. To calculate the p-values the 
data was controlled for age confounder by creating a linear regression model 
(ANCOVA). Correction for multiple testing was performed using Benjamini-Hochberg 
procedure with a 10% false positive rate.  
Missing values: There was one individual with missing age, menopause status, 
CA125, CRP and protein status. One individual had a missing menopause status. The 
small number of missing values were imputed using the K nearest neighbour approach 













where missing attributes were predicted. This is an acceptable procedure when the 
number of missing values are small.25 
Classification model: To classify individuals into normal, borderline or metastatic 
neural networks without hidden layers were trained with combinations of age, 
menopause status, logCA125, CRP, protein and glycan peak relative abundances. A 
one against all binary classification was performed (e.g. normal vs. 
borderline+metastatic). In order to test the performance of the models the data used 
to optimize parameters (train set) was split and a 10-fold cross validation (90% of data 
for training and 10% of data to test the model repeated 10 times) was performed. 
Discriminative power was calculated by Area under the Receiver Operating 
Characteristic (ROC) curve (AUC), sensitivity and specificity.  
Clustering: Principal component analysis was performed using variables peaks areas, 
age, logCA125, CRP, protein titre and menopause status.  For hierarchical clustering 
of the glycomic profiles, GP % areas were normalized to the range [0,1] and a 
hierarchy of clusters were built using the Ward algorithm26. Spearman correlations 
were used to calculate the similarity among GP, age, logCA125, CRP and protein titre. 
Therefore, correlated variables appear close together in the hieratical dendrogram 
produced by the clustering.  
 
Results and Discussion: 
GlycoSeqCap- automated N-glycan analysis platform using serial capture of 
individual serum glycoproteins  
We developed a technology termed “GlycoSeqCap” involving the serial capture and 
subsequent N-glycoprofiling of individual glycoproteins from human serum. The 
multiplexed automated serial capture of six abundant serum glycoproteins (the 
immunoglobulins, IgG, IgM, IgA, and the acute phase proteins, transferrin (Trf), alpha-
1-anti-trypsin (A1AT), haptoglobin (Hpt)) and N-glycan release from pooled human 
serum was optimised using a 96 well format on a robotic platform (Figure 1). Specific 
anti-glycoprotein capture resins (containing antibodies against specific glycoproteins) 
were packed in a series of PhyNexus phytips and each serum sample was passed 
successively through each resin in a sequential order Trf, IgG, IgM, IgA, Hpt and A1AT. 
The purified proteins, >98% pure as determined by 1D-SDS page, were then subjected 













to PNGaseF release, ultrafiltration and aminoquinoline carbamate (AQC) fluorescent 
labelling of the N-glycan pools using the Hamilton Starlet robotic system using a 
previously published protocol (Figure 1)11. These pools were subjected to hydrophilic 
ultra-high performance liquid chromatography (HILIC-UPLC) followed by 
exoglycosidase array glycan analysis according to the established procedures in our 
laboratory23. The UPLC chromatograms for the fluorescently labelled released N-
glycans of affinity purified glycoproteins (IgG, IgM, IgA, Trf, Hpt and A1AT) from human 
serum and the corresponding released N-glycans from total human serum21 are 
presented with annotations for the major N-glycans (Figure 2). 
Advantages and limitations of GlycoSeqCap technology 
This technological advancement provides N-glycosylation information for IgG, IgM, 
IgA, Trf, Hpt and A1AT and serves as a template for many other glycoproteins of 
interest which may find use as a personalized medicine tool for future applications. A 
major advantage of the developed workflow is the ability to have multiplexed glycomics 
information from a single clinical source. In addition, the Phytips are reusable and 
show good reproducibility over three consecutive runs and after 1 month of storage.  
However, one limitation regarding the extension of the technology to include other 
glycoproteins is the requirement for an affinity re 
sin with high selectivity and specificity for the targeted glycoprotein (e.g. antibodies or 
lectins) and in certain cases high amounts of biomaterial (in this case serum) may be 
required for lower abundant glycoproteins. In addition, the analyst must be cognisant 
of the purity of the targeted glycoprotein prior to enzymatic release of the N-glycans. 
For example, a recent publication cautions the users to account for the ubiquitous 
presence of varying levels of other contaminating plasma glycoproteins 27. In our 
study, we were careful to assess the purity of the glycoproteins by SDS-PAGE (Figure 
1) and systematically altered the number of capture, binding and wash steps to 
maximise purity prior to PNGase F release of N-glycans. As in the case of any affinity 
purification, it is possible that small traces of other glycoproteins have contributed to 
the N-glycan structures identified, albeit in tiny proportions. 
The glycosylation data for six abundant glycoproteins in normal human serum aligns 
nicely with the total glycan pool identified for human serum previously (Figure 2)21,28. 
All major glycans from human serum are identified in one/more of the individual 













glycoproteins that were characterized. In a large part, this identification on an 
individual glycoprotein level was enabled on such a small amount of serum (50µL) due 
to the use of a fluorescent label AQC which shows a twenty fold increase in fluorescent 
detection compared to the traditional label, 2-AB for released N-glycans which we 
have previously described for human IgG previously11,23. Various high-throughput 
large-scale studies have been conducted on a serum N-glycome level since 200929-31. 
These studies have yielded significant contributions to understanding the role of 
glycosylation in many diseases but cannot pinpoint the exact glycosylation processing 
pathways involved. On an individual glycoprotein level, large scale studies have 
focussed on IgG N-glycome only to date,32 leaving plenty of scope for future 
investigations on an individual glycoprotein level. In addition, it may also be possible 
to link significant alterations from the serum N-glycome to a specific glycoprotein by 
extrapolation using the major glycans identified in this work. 
Profiling and detailed N-glycan analysis of serum IgG, IgA and IgM  
In order to execute glycoprofiling to compare glycosylation of two distinct populations 
(such as serum IgG N-glycosylation from a normal population compared to an ovarian 
cancer cohort) it is important to generate reproducible profiles and fully characterize 
the N-glycomes. To this end, we have undertaken the most comprehensive study of 
released N-glycans for individual glycoproteins in human serum to date. UPLC 
chromatograms (for each individual glycoprotein) were integrated and split into glycan 
peaks (GPs) and each GP typically accounts for one or more glycans.  
The serum IgG N-glycome UPLC chromatogram was split into 25 GPs (adapted from 
a literature procedure using 23 GPs11) to account for N-glycans prominent in IgG 
human serum from patients with ovarian cancer. The 25 IgG GP areas (G1-G25) were 
plotted for five technical replicates over three different days to provide standard error 
bars on the integrated peak areas (Figure 3a, Supporting Table S7). The majority of 
the GPs (21/25) are strongly reproducible for the technical replicates with coefficient 
of variance (CV) values for each GP below 25% with the exceptions of GPs G1, G15 
and G25. These GPs cumulatively account for a small amount (0.35%) of the total 
peak area of IgG N-glycome in the technical replicates. Characterization proceeded 
as follows: the preliminary structures,  assigned from glucose unit (GU) values 
(obtained by matching elution positions to a standard dextran hydrolysate curve and 













using Glycobase software (data now migrated to Glycostore 
(https://www.glycostore.org/)33), were confirmed by exoglycosidase array digestions 
(Figure 3b) and intact mass using electrospray (ESI-LC) liquid chromatography mass 
spectrometry (Supporting Table S1). They are in agreement with literature11,32 (with 
the addition of a high mannose species (M7) not previously identified) and are 
presented in Supporting Table S6. 
The equivalent data for serum IgM and IgA N-glycomes were split into 24 (M1-M24) 
and 25 (A1-A25) GPs respectively and are shown in Figure 3 (reproducibility data in 
Supporting Table S7). For IgM, all GPs (M1-M24) show good reproducibility for the 
technical replicates (below 25%). Similarly IgA shows good reproducibility for all major 
GPs (A2-A25, below 25%) but exhibits slightly higher CVs for the first and last GPs 
(A1, A25) accounting for 0.92% of the total IgG N-glycome. Structural assignments of 
IgM and IgA N-glycans were characterised in a similar manner to serum IgG using GU 
values and LC-MS (Supporting Table S2 and S3) and are presented in Supporting 
Table S6. For serum IgM, structural assignment of N-glycans were in agreement with 
the previously reported literature values15 with some additional glycans identified in 
our analysis (13 newly characterized compositions out of a total of 53) including some 
of the M5A1 Series (M5A1, M5A1G1 and M5A1G1S(6)1), FA1 Series (FA1, FA1G1 
and FA1G1S1), A2 Series (A2G1S(6)1 and A2G2S(6,6)2) and the A2B Series 
(A2BG1S(6)1). For IgA, structural assignment of N-glycans were in agreement with 
the literature reports previously described16,17,34. As in the case of IgM, additional 
glycans were identified (16/55) in our in-depth analysis not previously described in the 
literature including some monoantennary and biantennary species (A1, A2[6]G1, 
A2[3]G1, FA2),  hybrid species (M4A1, M4A1G1, M4A1G1S(6)1, M4A1BG1, 
M5A1G1, M5A1G1S(6)1), A3 Series (A3, A3G2, A3G2S(6)1, A3G3S2, FA3) and M10.  
Profiling and detailed N-glycan analysis of serum Trf, Hpt and A1AT  
The acute phase proteins, Trf, Hpt and A1AT were purified from human serum by 
serial extraction as described earlier and the released N-glycans labelled with AQC 
analysed by UPLC-HILIC. The 28 Trf (T1-T28), 31 Hpt (H1-H31) and 28 A1AT (AT1-
AT28) glycan peak areas were plotted for at least five technical replicates over three 
different days to provide the standard error bars (Figure 4a,b and reproducibility data 
in Supporting Table S7). All GPs in Trf, Hpt show good reproducibility (CV below 25%) 













except GPs T1 and T5 (total glycan peak area of 0.03%) in Trf and H5 (glycan peak 
area of 0.02%) in Hpt, accounting for very minor constituents of the total N-glycome in 
the technical replicates. The reproducibility of A1AT N-glycome is the lowest (being 
the last glycoprotein to be purified in the sequence) with only 19/28 glycan peaks 
exhibiting good reproducible CV values below 25%. The remainder (AT1, AT3-5, AT8-
10, AT12, AT14) accounts for a total of 2.67% of the total A1AT N-glycome, a relatively 
small proportion of the total N-glycome.  
The AQC labelled Trf, Hpt and A1AT (Figure 4) N-glycan pools were sequenced using 
exoglycosidase arrays and the data combined with glucose unit (GU) values and LC-
MS to facilitate glycan identification. As for the immunoglobulins, many newly identified 
N-glycans are presented as well as agreement with the major glycans already 
presented in the literature for Trf 8,Hpt8,35 and A1AT8,36. The list of newly identified 
glycans are highlighted with a Δ symbol in Supporting Tables S6. For Trf, 28 out of 48 
glycan compositions are identified for the first time in this publication. Most 
significantly, we identify the FA3G3 series not identified for Trf previously which 
accounts for almost 4% of the total N-glycome. Similarly, for Hpt and A1AT, 32/47 and 
28/44 glycan compositions are identified respectively for the first time. For Hpt, the 
FA3 series is significant accounting for approx. 3% of the total N-glycome and the 
newly identified glycan A3F1G3S3 accounts for approx. 2% of the peak area. 
Comparison of glycosylation between antibody classes: IgG, IgM and IgA 
We probed the glycosylation of selected antibodies to gain an insight into the structure-
function relationship of antibody classes. One important point to consider is that serum 
glycoproteins are a combination of active components and waste products and this 
may complicate interpretations. Structural similarities and differences in antibody 
glycosylation of IgG, IgM and IgA are presented for pooled normal human serum 
(Figure 5a,b). The derived glycosylation traits were generated from UPLC data 
(Supporting Tables S6) and calculated from the summation of individual GPs for each 
glycoprotein (Supporting Table S8). Striking variation in glycosylation traits such as 
galactosylation, fucosylation, sialylation, bisecting GlcNAcs (glycans with bisecting N-
acetylglucosamine residues), high mannose, hybrid or the degree of branching 
(monoantennary, biantennary, triantennary) can be observed. Overall, all antibodies 
exhibit a high proportion of biantennary structures (˃60%) with little/no 













monoantennary/triantennary structures, as documented previously in the 
literature15,32,34. Additionally, a high degree of galactosylation is observed for all three 
glycoproteins (˃60%). Only α2,6-linked sialic acids (containing the Neu5Ac form) and  
no corresponding α2,3-linked sialic acids are identified for IgG or IgM which is 
consistent with literature reports15,32. Additionally, only minor species contained α2,3-
linked sialic acids in IgA, as identified previously17. Increased sialylation was observed 
from IgG to IgM to IgA (22%, 60% and 85% respectively). IgG contains the highest 
proportion of core fucosylation (93%) relative to IgM or IgA (58% and 28% 
respectively)  and no outer arm fucose were identified for the serum antibody series. 
This observation is consistent with other reports for serum antibodies15,17,32. IgA 
contains the highest abundances of bisecting GlcNAcs (52%) and galactose residues 
(93%) and a very small proportion of triantennary structures (0.9%) not observed for 
the other antibodies. IgM exhibits the lowest amount of biantennary structures (64%) 
and galactosylation (65%) but significantly higher amounts of high mannose structures 
(31%). 
Acute phase protein glycosylation traits: Trf, Hpt and A1AT 
Unlike the selected antibodies which share structural similarities in terms of their 
protein structure, the selected acute phase proteins (Trf, Hpt and A1AT) have less 
commonality and exhibit more varied glycosylation traits. These structural similarities 
and differences are presented for pooled normal human serum (Figure 5a,c). As for 
the antibodies, a high degree of galactosylation was observed (˃95%) for selected 
acute phase proteins but relatively low amounts of total fucosylation (˂20%) were 
identified, accounting for a combination of core fucose and the outer arm fucose 
residues (not identified in the selected serum antibodies in this study). Sialyl Lewisx 
(SLex) motifs (Neu5Acα2-3Galβ1-4[Fucα1-3]GlcNAcβ), which contain outer arm 
fucose residues,  are identified in human serum acute phase proteins, albeit in small 
proportions. Notably, as in the case for the antibody glycosylation, α2,6-linked sialic 
acids (˃65%) are dominant over the corresponding α2,3-linked sialic acids (˂10%) of 
the annotated sialic acids. In previous studies of acute phase proteins, many sialic 
acid linkage types were left ambiguous8,35, as such we provide the most extensive 
breakdown to date for acute phase protein N-glycosylation. A larger proportion of 
higher branched structures are observed such as triantennary structures (˃10%) and 
the presence of tetraantennary glycans are observed. Hpt exhibits the highest relative 













amount of both triantennary (22%) and tetraantennary (6%) structures compared to 
Trf or A1AT. 
Glycosylation traits for functional studies 
The quantification of glycosylation traits for a series of glycoproteins is presented here 
for the first time from a single source of human serum (Figure 5). One can envisage 
this information as being a starting point for functional studies to investigate the 
specific role of glycosylation in our immune system and has the added advantage over 
traditional approaches in glycoanalytics to explore the effect of more than one 
glycoprotein in a single experiment. For example, little is known about how the most 
abundant antibody isotypes in human serum (IgG, IgM and IgA) compete for antigens 
but using quantified glycan traits, combined with antibody-antigen assays could 
provide a clearer picture for the role of glycosylation in this context. From our 
glycosylation traits alone, it is impossible to predict biological function but it may 
provide a basis for further investigations. For example, taking into consideration 
functional examples of afucosylation of IgG1 increasing antibody-dependent cellular 
cytotoxicity (ADCC)37,38,  and looking at levels of antibody fucosylation in human 
serum, the striking difference between IgG (93%) and IgM or IgA core fucosylation 
(58% and 28% respectively) may hint that serum IgA recruit effector cells for ADCC  
more efficiently compared to IgG or IgM. Importantly, it must be considered that we 
have measured only in human serum samples and this data does not necessarily 
reflect on a tissue/cell specific antibody glycosylation level. In addition to core 
fucosylation, we reported no outer arm fucose for the antibody classes. Noteworthy, 
outer arm fucosylation has been reported for secretory component (SC) N-glycans of 
IgA, but none for the corresponding J or H chain N-glycans34. It is known that serum 
IgA is predominantly monomeric and does not contain the J chain and the SC and as 
such we report no conflicting findings in this study. Another interesting differentiation 
between the glycosylation traits of the antibody isotypes is the high abundance of 
sialylation for IgA (85%) relative to IgM (60%) and IgG (22%).  We propose that serum 
IgA uses electrostatic interactions and steric obstruction/adhesion as the main 
mechanistic mode for fighting infection but it is not clear if this sialylation is employed 
for antigen binding/effector function purposes. A more in-depth analysis for Fc and 
Fab N-glycosylation of serum IgA would shed more light in this regard. Lastly for the 
antibody class, we reported the highest proportion of high mannose structures (31%) 













for serum IgM. This proportion of high mannose was higher than the value of 23% 
previously reported for serum IgM and the corresponding amount of galactosylation 
was lower (65%) compared to the literature value of 84%15. We suggest that advances 
in modern technology have allowed for a more accurate and precise assignment of N-
glycans in our study- however it cannot be ignored that the human serum populations 
used in the two studies may have been different.  
In contrast with immunoglobulins, which are mainly produced by B-cells, major plasma 
glycoproteins including Trf, Hpt and A1AT originate from hepatocytes, which express 
only very low levels of the FUT8 fucosyltransferase and thus contain a low percentage 
of core fucosylated glycans 32. As anticipated, we observed lower levels of core fucose 
for the acute phase proteins in comparison to the antibody classes in our study (Figure 
5). Another interesting point relates to the increased complexity of the acute phase 
protein N-glycosylation compared to immunoglobulin classes (Figure 5), with 
tetraantennary glycans present in these glycoproteins not isolated from the antibody 
classes. We cannot find a biological rationale for the reasons as to why the N-glycans 
are more branched in these acute phase proteins but it may be related to their 
inflammatory properties. Also, these glycoproteins contain SLex motifs. SLex are 
known to play a vital role in cell-cell recognition and other processes and are known 
to be overexpressed in cancer cells39. As such, this feature is particularly important in 
the context of our ovarian cancer cohort. 
 
Glycoprofiling and statistical significance of selected glycoproteins in ovarian 
cancer 
Having comprehensively assigned N-glycans and calculated derived glycosylation 
traits for the selected glycoproteins IgG, IgM, IgA, Trf, Hpt and A1AT in normal human 
serum, we glycoprofiled a cohort of patients with ovarian cancer to exploit the 
quantifiable N-glycosylation alterations for a) detection of ovarian cancer and b) to 
differentiate between stage of the disease in an effort to provide a clinical tool for early 
diagnosis in the future.  
The N-glycome of selected proteins (IgG, IgM, IgA, Trf, Hpt and A1AT) from 7 normal 
controls and 27 ovarian cancer patients (either classified as borderline or metastatic 
presented in biological manifest in Supporting Table S9) as a test group were analysed 













resulting in a total of 204 processed glycoprofiles. The profiles were split into glycan 
peaks (GPs) according to the individual glycoproteins (e.g. G1-G25 for IgG) and the 
values are presented  as a proportion of total % peak area in Supporting Tables  S10-
S15 for glycoproteins IgG, IgM, IgA, Trf, Hpt and A1AT respectively. The derived 
glycosylation traits were also calculated and were derived as described earlier 
(Supporting Table S8). Controlling for age, the statistical significance (Tukey honest 
significant difference (HSD) with ANOVA, normally distributed (data not shown)) was 
measured for all GPs and glycosylation traits for each selected glycoprotein and are 
presented in Supporting Tables S16-S21, as well as for the clinical variables 
(Supporting Table S22) between normal vs. borderline, metastatic vs. borderline, 
normal vs metastatic clinical samples. The p-values were corrected for multiple testing 
error, using a 5% false discovery rate (FDR) approach proposed by Benjamini-
Hochberg40.  An adjusted p<0.05 was considered statistically significant. Significant 
GPs, glycosylation traits and clinical parameters for the patients are presented in 
Figure 6 for the glycoprotein series. Boxplots (6c) and the major glycan (6b) for the 
statistically significant GPs/glycosylation traits are also presented.  
From the glycoproteins selected, Trf shows the best discrimination between normal 
patients (n=7) and borderline (n=6) or metastatic patients (n=21). Most notably, Trf 
glycosylation can distinguish between normal and borderline samples using four 
individual GPs (T11, T16, T17 and T18), whereby CA125, the gold standard for 
ovarian cancer detection does not show the same statistical significant separation. 
Fucosylation also stands out as a feature that may be exploited for this discrimination. 
The GPs/glycosylation features of Trf cannot differentiate between metastatic and 
borderline samples in this cohort however, whereas CA125 does show a significance.  
Several studies have presented evidence implicating Trf in ovarian cancer biology 41. 
In addition, alterations in Trf glycosylation in the context of cancer and other 
inflammatory diseases have been reviewed in the literature 36,42. Taken together, Trf 
sialylation is often altered in disease states and is no exception in this study, whereby 
sialic acid (α2,6) is altered in the metastatic cancer cohort compared to normal 
controls. Since desialylated Trf has faster clearance, it may be an evolutionary tactic 
of bacteria/pathogens to contribute to oncogenesis. What is more striking in our study 
is the alterations of Trf fucosylation. Trf fucosylation has been shown to be 
dysregulated in diseases such as classical galactosemia43 but to the best of our 













knowledge has not been reported in the context of ovarian cancer to date. Future 
studies are warranted to investigate further. 
In addition, haptoglobin glycosylation is significantly altered in metastatic cancer 
(n=18) compared to normal patients (n=7) in this cohort by six distinct GPs (H2, H3, 
H11, H20, H21 and H22) as well as glycosylation features fucosylation and SLex motif. 
This data is consistent with literature reports44, whereby the main glycosylation 
alterations of Hpt in cancer appear to be the presence of aberrantly fucosylated and 
sialylated structures as well as increased branching. 
Discrimination and cluster analysis in ovarian cancer 
A discrimination analysis was explored for the probabilistic classification of healthy 
(normal) vs ovarian cancer samples using the glycosylation data and comparing to 
CA125 values for the clinical cohort. CA125 antigen is a high molecular weight 
glycoprotein, which is expressed by a large proportion of epithelial ovarian cancers 
and is currently regarded as the golden standard for ovarian cancer diagnosis, 
despite its poor sensitivity and specificity. It is only raised in approximately 50% of 
stage 1 epithelial ovarian cancers and in 75–90% of patients with advanced disease 
and false positive results have been noted in many medical disorders, both 
malignant and benign45. The area under the ROC curve (AUC), sensitivity (SEN) 
and specificity (SPE) were calculated and associated with normal vs. borderline, 
metastatic vs borderline and normal vs. metastatic clinical samples (Supporting 
Table S23, S24 and S25 respectively). The individual models performed well with 
regards to distinguishing normal from borderline patients, with the most promising 
result using derived traits from Hpt (AUC=1.000, SEN=1.000 and SPE=1.000) (Figure 
7a). This finding, if validated could have major ramifications for early detection of 
ovarian cancer using Hpt glycosylation. Similarly, good discrimination was observed 
for normal vs metastatic patients. Again Hpt showed perfect discrimination for all 
peaks, derived traits and combinations thereof. However, CA125 also allows perfect 
discrimination so this negates the glycome data in this instance. No glycosylation 
feature could discriminate between borderline and metastatic patients and superior 
results were observed for CA125 in this case. 
Cluster analysis was performed using principal component analysis (PCA) and 
hierarchical clustering. PCA results are provided in Supporting Figures S7-S12, and 













hierarchical clustering is presented in Supporting Figures S13-S18 for the respective 
glycoproteins IgG, IgM, IgA, Trf, Hpt and A1AT for individual glycan peaks. No clear 
discrimination was observed between normal, borderline or metastatic samples for 
PCA analysis on individual glycan peaks. For hierarchical clustering, no major 
clustering was observed for glycoproteins IgG, IgM or A1AT but clustering was 
observed for IgA, Trf and Hpt with clear clustering of metastatic and normal samples 
respectively with the most pronounced affect for Hpt. Taking glycosylation traits into 
consideration, Hpt again outperforms the other glycoproteins and PCA plots are shown 
in Figure 7b showing a clear separation for normal and borderline samples and normal 
and metastatic samples but no separation between borderline vs metastatic samples, 
consistent with the AUC, SEN and SPE observed for this dataset. 
Glycoanalytical diagnostic tools for ovarian cancer 
The availability of diagnostic tools for ovarian cancer remains somewhat elusive. 
CA125 is currently the best diagnostic tool for ovarian cancer on the market, but is not 
reliable for diagnosing early stage ovarian cancer46,47. Early stage detection and 
subsequent treatment of ovarian cancer is an attractive approach to reduce morbidity 
from ovarian cancer. In this study, we corroborate these literature findings and show 
that CA125 cannot differentiate between borderline (n=6) and normal (n=7) samples 
(Figure 6). For IgG, IgA, IgM, Hpt and A1AT, again we cannot see any significant 
alterations between these classes but find instead that Trf glycosylation can 
discriminate using GPs T11, T16, T17 and T18 (Figure 6) in our small clinical cohort. 
If these findings could be replicated and validated, Trf glycosylation could be exploited 
as an early detection tool for ovarian cancer. To probe the potential role of Trf 
glycosylation in ovarian cancer on a very basic level, we measured the 
upregulation/downregulation of the relative abundance of N-glycans for the statistically 
significant GPs (Figure 6b) and hypothesize that the dominant glycosylation features 
may be significant in the progression of the disease. Two of the major glycans that are 
upregulated in the borderline samples (n=6) contain core fucose- FA2G2 (T11) and 
FA2G2S(6)1 (T16) whereas there is a corresponding decrease in afucosylated 
structure A2G2S(3,6)2 (T18). Taking the classification and clustering data into 
consideration Trf glycosylation does not provide superior differentiation between 
classes compared to the other glycoproteins- no clear PCA differentiation is observed 













(Supporting Figure S10) but the hierarchical clustering does show its promise for 
resolving power between the groups (Supporting Figure S16). 
 
With respect to clustering and classification analysis, the best performer is Hpt 
glycosylation (Figure 7) which displays clear groupings in the PCA analysis. In 
addition, regarding the statistical findings for Hpt glycosylation, there is a notable 
increase in two core fucosylated species FA2G2 (H11) and FA2G2S(6,6)2 (H20) in 
metastatic cancer patients (n=18) compared to normal controls (n=7) and a decrease 
in the afucosylated complex glycan A3G3S2 (H22). Taken collectively, this data 
suggests that core fucosylation (the FA2 Series) is significantly upregulated in this 
ovarian cancer cohort in both Trf and Hpt. Importantly, FA2 was previously found to 
be significantly altered (increased) in sera of ovarian cancer patients using an 
independent N-glycoanalytical technology46. We propose these changes reflect either 
differences in the expression levels of the α(1-6)-fucosyltransferase (FUT8) or donor 
substrate (GDP-fucose) in the medial-Golgi in ovarian cancer specific cells.  
 
As discussed above, Trf glycosylation is the most significantly altered in our study and 
Hpt shows the greatest promise with respect to cluster analyses from the selected 
acute phase proteins and antibodies in the discrimination of ovarian cancer stages. 
Both glycoproteins warrant further functional studies in the future. Remarkably, very 
few investigations are described in the literature with respect to the possible role of Trf 
in ovarian cancer, despite its use as part of a commercial product, a multivariate index 
assay called OVA1 (approved by the FDA in 2016) which incorporates five serum 
biomarkers into a malignancy risk score of 0–10 using a proprietary algorithm and is 
recommended by the American College of Obstetricians and Gynecologists48 as a tool 
to aid in evaluating women with adnexal masses. There is precedence of altered 
expression of Hpt glycosylation in ovarian cancer whereby Turner and colleagues 
found enhanced expression of branching, especially triantennary glycans in patients 
with ovarian cancer49. As such Trf and Hpt present as interesting targets for ovarian 
cancer treatment. Regarding the remaining glycoproteins, IgG, IgM and IgA 
glycosylation were assessed previously in the context of ovarian cancer from late 
stage patients only-the results indicated that combining IgG glycosylation profiles with 
CA-125 could improve accuracy of epithelial ovarian cancer prediction18, in contrast to 
our findings. In a separate study, IgG galactosylation was used to assist a differential 













diagnosis of ovarian cancer with CA-12550. A very early study investigated A1AT 
glycosylation in the context of ovarian cancer51. The authors concluded that 
fucosylation was a glycosylation feature that became elevated in the presence of 
tumour growth but remained low in remission and during chemotherapy. This study 
does not reflect the utility of A1AT fucosylation in the selected cohort of patients. 
Conclusion: 
This study presents the development of an elegant glycoanalytical platform for the 
detailed characterisation and investigation of a sequence of glycoprotein N-
glycosylation: antibodies IgG, IgM and IgA and acute phase proteins Trf, Hpt and 
A1AT. In the course of this analysis, besides achieving a detailed glycoprofile for each 
glycoprotein through the identification and profiling of more than a hundred glycan 
structures, we were able to identify novel glycan motifs and traits that have not been 
outlined to date. Its utility in the context of ovarian cancer is highlighted-Trf and Hpt 
glycosylation can be exploited as biomarker tools for ovarian cancer and may play a 
cardinal role. More importantly, this comprehensive and reproducible glycoprofiling 
technology could provide significant insights and serve as a baseline for the 
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 Figures: 
Figure 1. Multiplexed automated serial capture of glycoprotein N-glycoprofiling. 96-well format robotic platform (A), 
specific anti-glycoprotein capture resin packed in PhyNexus phytip (B), serial capture of selected glycoproteins 
1.Trf, 2.IgG, 3.IgM, 4.IgA, 5.Hpt, 6.A1AT (C), 1D SDS-PAGE separation of multiplexed automated capture of six 
selected glycoproteins from pooled human serum using PhyNexus Phytips. Lane 1: Protein Marker, Lane 2: Trf 
Standard, Lane 3:  Bound Trf, Lane 4:  Bound IgG,  Lane 5:  Bound IgM, Lane 6:  Bound IgA, Lane 7:  A1AT 
Standard, Lane 8:  Bound A1AT, Lane 9:  Hpt Standard, Lane 10:  Bound Hpt. The protein bands marked with 
arrows are traces of albumin protein (non-glycosylated) (D), automated glycoprotein sample preparation, PNGaseF 
release and aminoquinoline carbamate (AQC) labelling of N-glycans (E) and finally ultra-high performance liquid 
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Figure 2. UPLC-HILIC-FLD chromatograms of AQC labelled N-glycans released from human serum for affinity 
purified glycoproteins IgG, IgM and IgA, Trf, Hpt, A1AT and 2-AB labelled N-glycans released from total serum. 
Only major glycans are annotated. All major N-glycans identified within the total serum UPLC chromatogram are 
present in the individual glycoprotein chromatograms which showcases that serum glycosylation is largely 
















































Figure 3. Serial capture and N-glycoprofiling of human serum IgG, IgM and IgA, purified from human serum. The 
25 IgG glycan peak areas (G1-G25), 24 IgM peak areas (M1-24) and 25 IgA glycan peak areas (A1-A25) plotted 
for five technical replicates over three different days (3a). The standard error shown as error bars. Sequencing of 
AQC labelled IgG, IgM and IgA N-glycans visualized by UPLC-HILIC chromatograms using exoglycosidase 
enzymes with glucose units (GU) to facilitate glycan identification (3b). Digestion of AQC labelled IgG, IgM and IgA 
N-glycans with addition of sialidase (ABS), galactosidase (BTG), hexosaminidase (GUH), fucosidase (BKF) and 
mannosidase (JBM) in the following order ABS, ABS+BTG, ABS+BTG+GUH, ABS+BTG+GUH+BKF and 
ABS+BTG+GUH+BKF+JBM. For IgG, arrows indicate the cleavage of sugar residues for selected peaks: major 
glycans FA2G2S1 and FA2G2S2. For IgM, arrows indicate the cleavage of sugar residues for selected peaks: 
major glycans FA2G2S1 and FA2BG2S1. For IgA, arrows indicate the cleavage of sugar residues for selected 
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Figure 4. Serial capture and N-glycoprofiling of human serum Trf, Hpt and A1AT, purified from human serum. The 
28 Trf glycan peak areas (T1-T28), 31 Hpt glycan peak areas (H1-H31) and 28 A1AT glycan peak areas (AT1-
AT28) were plotted for five technical replicates over three different days (4a). The standard error shown as error 
bars. Sequencing of AQC labelled Trf, Hpt and A1AT N-glycans visualized by UPLC-HILIC chromatograms using 
exoglycosidase enzymes with glucose units (GU) to facilitate glycan identification (4b). Digestion of AQC labelled 
Trf, Hpt and A1AT N-glycans with addition of sialidase (ABS), galactosidase (BTG), hexosaminidase (GUH), 
fucosidase (BKF) and mannosidase (JBM) in the following order ABS, ABS+BTG, ABS+BTG+GUH, 
ABS+BTG+GUH+BKF and ABS+BTG+GUH+BKF+JBM. In Trf, arrows indicate the cleavage of sugar residues for 
selected peaks: major glycans A2G2S(3,6)2 and A2G2S2(6,6)2. In Hpt, arrows indicate the cleavage of sugar 
residues for selected peaks: major glycans A3G3S3, A2G2S2 and A2G2S1. In A1AT, arrows indicate the cleavage 
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Figure 5. Glycosylation traits for selected antibodies (IgG, IgM, IgA) and acute phase proteins (Trf, Hpt, A1AT) for 
healthy human serum are presented (5a). The values are represented as a % of the total glycosylation and are 
calculated from data provided in Supporting Table S15. Glycosylation features of antibodies (IgG, IgM and IgA) 
and acute phase proteins (Trf, Hpt, A1AT) are presented as control charts (5b and 5c). 
 
 
Glycan Traits IgG IgM IgA Trf Hpt A1AT
Galactosylation 75.44 65.27 92.87 98.31 96.87 97.77
Fucosylation 92.80 58.21 28.22 8.07 16.16 14.48
Bisecting 16.87 32.48 52.09 1.13 0.31 3.44
Monoantennary 0.09 2.72 0.31 0.97 0.96 1.09
Biantennary 99.78 63.75 97.28 89.94 67.93 80.62
Triantennary 0.00 0.00 0.90 7.04 22.45 12.14
High Mannose 0.00 30.98 2.58 1.01 2.77 1.92
SLex Motit 0.00 0.00 0.00 1.56 1.48 0.65
Sialic Acid (α2-3) 0.00 0.00 0.00 11.57 6.24 5.19
Sialic Acid (α2-6) 21.99 60.20 84.87 71.85 65.43 78.99
Sialic Acid (unknown 
Linkage)
0.00 0.00 0.90 8.13 27.16 15.13
Hybrid 0.00 1.94 0.29 0.38 0.00 0.97




















































Figure 6. Statistically significant GPs and glycosylation traits for each glycoproteins and clinical parameters 
(Y=yes) with p-values <0.05 (corrected for multiple testing error using a 5% FDR proposed by Benjamini-
Hochberg40) for ovarian cancer cohort of normal vs. borderline, metastatic vs. borderline and normal vs. metastatic 
(6a). The major glycan for the each statistically significant GP is presented (6b). Boxplots are presented for the 
statistically significant GPs, glycosylation traits and logCA125 for borderline (red), metastatic (green) and normal 









Normal vs. Borderline Metastatic vs. Borderline Normal vs. Metastatic
IgG - - -
IgM - - -
IgA - - -
Trf T11, T16, T17, T18, fucosylation -
T10, T11, T12, T16, T17, T18, T19, T27, fucosylation, biantennary, 
sialic acid (α2,6)
Hpt - - H2, H3, H11, H20, H21, H22, fucosylation, SLex
A1AT - - -
Age - - -
CA125 - Y Y
CRP - - -
Protein - - -










T17=A3G3S(6)1 T18=A2G2S(3,6)2 T19=A2G2S(6,6)2 T27=A3G3S3 H22=A3G3S2
H3=M5H2=A1G1













Figure 7. Discrimination performance for noteworthy glycosylation traits (Hpt) for ovarian cancer cohort of normal 
vs. borderline, normal vs. metastatic and borderline vs metastatic. Linear regression model including AUC, SEN 
and SPE (7a), cluster analysis using PCA using Hpt derived traits as input for normal (blue, n=7) vs. borderline 
(orange, n=6) separation, normal (blue, n=7) vs. metastatic (orange, n=18) and borderline (orange, n=6) vs 





Log CA125 All peaks Derived traits
Hpt AUC:0.667 AUC:0.976 AUC:1.000
Normal (n=7) SEN:0.667 SEN:0.833 SEN:1.000
Borderline (n=6) SPE:1.000 SPE:1.000 SPE:1.000
Hpt AUC:1.000 AUC:1.000 AUC:1.000
Normal (n=7) SEN:1.000 SEN:1.000 SEN:1.000
Metastatic (n=18) SPE:1.000 SPE:1.000 SPE:1.000
Hpt AUC:0.917 AUC:0.440 AUC:0.694
Borderline (n=6) SEN:0.889 SEN:0.667 SEN:0.556
Metastatic (n=18) SPE: 1.000 SPE:0.500 SPE:0.833
a)
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